Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381243100> ?p ?o ?g. }
- W4381243100 endingPage "5217" @default.
- W4381243100 startingPage "5210" @default.
- W4381243100 abstract "Purpose Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer. Patients and Methods Seven hundred fifty-two patients were randomly assigned to ixabepilone 40 mg/m 2 intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m 2 orally on days 1 through 14 of a 21-day cycle, or capecitabine alone 2,500 mg/m 2 on the same schedule, in this international phase III study. The primary end point was progression-free survival evaluated by blinded independent review. Results Ixabepilone plus capecitabine prolonged progression-free survival relative to capecitabine (median, 5.8 v 4.2 months), with a 25% reduction in the estimated risk of disease progression (hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P = .0003). Objective response rate was also increased (35% v 14%; P < .0001). Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [≥ grade 2 liver function tests] at greater risk). Capecitabine-related toxicities were similar for both treatment groups. Conclusion Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes." @default.
- W4381243100 created "2023-06-20" @default.
- W4381243100 creator A5003980305 @default.
- W4381243100 creator A5004874011 @default.
- W4381243100 creator A5007609170 @default.
- W4381243100 creator A5032293735 @default.
- W4381243100 creator A5035238172 @default.
- W4381243100 creator A5044903892 @default.
- W4381243100 creator A5047830459 @default.
- W4381243100 creator A5049679970 @default.
- W4381243100 creator A5052648400 @default.
- W4381243100 creator A5055661870 @default.
- W4381243100 creator A5055883592 @default.
- W4381243100 creator A5056927697 @default.
- W4381243100 creator A5060759473 @default.
- W4381243100 creator A5061506787 @default.
- W4381243100 creator A5062352551 @default.
- W4381243100 creator A5071553983 @default.
- W4381243100 creator A5088787478 @default.
- W4381243100 date "2007-11-20" @default.
- W4381243100 modified "2023-10-10" @default.
- W4381243100 title "Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment" @default.
- W4381243100 cites W1939003096 @default.
- W4381243100 cites W1966574632 @default.
- W4381243100 cites W1978716373 @default.
- W4381243100 cites W2014896707 @default.
- W4381243100 cites W2033346155 @default.
- W4381243100 cites W2085044126 @default.
- W4381243100 cites W2103799380 @default.
- W4381243100 cites W2110444464 @default.
- W4381243100 cites W2114159573 @default.
- W4381243100 cites W2114826333 @default.
- W4381243100 cites W2119609398 @default.
- W4381243100 cites W2119974083 @default.
- W4381243100 cites W2131597845 @default.
- W4381243100 cites W2131770017 @default.
- W4381243100 cites W2138929540 @default.
- W4381243100 cites W2140837341 @default.
- W4381243100 cites W2145042104 @default.
- W4381243100 cites W2225369932 @default.
- W4381243100 cites W2227533786 @default.
- W4381243100 cites W2302447289 @default.
- W4381243100 cites W2314318352 @default.
- W4381243100 cites W4232095946 @default.
- W4381243100 doi "https://doi.org/10.1200/jco.2007.12.6557" @default.
- W4381243100 hasPublicationYear "2007" @default.
- W4381243100 type Work @default.
- W4381243100 citedByCount "233" @default.
- W4381243100 countsByYear W43812431002012 @default.
- W4381243100 countsByYear W43812431002013 @default.
- W4381243100 countsByYear W43812431002014 @default.
- W4381243100 countsByYear W43812431002015 @default.
- W4381243100 countsByYear W43812431002016 @default.
- W4381243100 countsByYear W43812431002017 @default.
- W4381243100 countsByYear W43812431002018 @default.
- W4381243100 countsByYear W43812431002019 @default.
- W4381243100 countsByYear W43812431002020 @default.
- W4381243100 countsByYear W43812431002021 @default.
- W4381243100 countsByYear W43812431002022 @default.
- W4381243100 countsByYear W43812431002023 @default.
- W4381243100 crossrefType "journal-article" @default.
- W4381243100 hasAuthorship W4381243100A5003980305 @default.
- W4381243100 hasAuthorship W4381243100A5004874011 @default.
- W4381243100 hasAuthorship W4381243100A5007609170 @default.
- W4381243100 hasAuthorship W4381243100A5032293735 @default.
- W4381243100 hasAuthorship W4381243100A5035238172 @default.
- W4381243100 hasAuthorship W4381243100A5044903892 @default.
- W4381243100 hasAuthorship W4381243100A5047830459 @default.
- W4381243100 hasAuthorship W4381243100A5049679970 @default.
- W4381243100 hasAuthorship W4381243100A5052648400 @default.
- W4381243100 hasAuthorship W4381243100A5055661870 @default.
- W4381243100 hasAuthorship W4381243100A5055883592 @default.
- W4381243100 hasAuthorship W4381243100A5056927697 @default.
- W4381243100 hasAuthorship W4381243100A5060759473 @default.
- W4381243100 hasAuthorship W4381243100A5061506787 @default.
- W4381243100 hasAuthorship W4381243100A5062352551 @default.
- W4381243100 hasAuthorship W4381243100A5071553983 @default.
- W4381243100 hasAuthorship W4381243100A5088787478 @default.
- W4381243100 hasBestOaLocation W43812431001 @default.
- W4381243100 hasConcept C121608353 @default.
- W4381243100 hasConcept C126322002 @default.
- W4381243100 hasConcept C143998085 @default.
- W4381243100 hasConcept C168563851 @default.
- W4381243100 hasConcept C203092338 @default.
- W4381243100 hasConcept C207103383 @default.
- W4381243100 hasConcept C2775930923 @default.
- W4381243100 hasConcept C2776802502 @default.
- W4381243100 hasConcept C2777063308 @default.
- W4381243100 hasConcept C2777511904 @default.
- W4381243100 hasConcept C2777909004 @default.
- W4381243100 hasConcept C2779194965 @default.
- W4381243100 hasConcept C29730261 @default.
- W4381243100 hasConcept C44249647 @default.
- W4381243100 hasConcept C526805850 @default.
- W4381243100 hasConcept C530470458 @default.
- W4381243100 hasConcept C71924100 @default.
- W4381243100 hasConcept C90924648 @default.
- W4381243100 hasConceptScore W4381243100C121608353 @default.